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Background: Urinary kidney injury molecule-1 (KIM-1) is an early and sensitive
biomarker of acute kidney injury, but it is unclear if it is a biomarker of chronic
glomerulonephritis. We evaluated whether urinary KIM-1 levels in patients with
immunoglobulin A (IgA) nephropathy can be a marker to reﬂect clinicopathological
severity and predict the prognosis.
Methods: We measured urinary KIM-1 levels in 40 patients (15 males; mean age
36.6712.9 years) with IgA nephropathy and 10 healthy people (5 males; mean age
37.379.6 years) as controls. The correlation of urinary KIM-1 levels with patients’
clinical parameters, histological grades, and follow-up data were analyzed using the
modiﬁed H. S. Lee grading system and tubulointerstitial change scores.
Results: Urinary KIM-1 levels were higher in patients with IgA nephropathy than
healthy controls (P¼0.001). Univariate and multivariate regression analyses showed
that urinary KIM-1 levels had a direct correlation with H. S. Lee grade and
tubulointerstitial inﬂammation (P¼0.004 and P¼0.011, respectively).
Conclusion: In patients with IgA nephropathy, urinary KIM-1 has a signiﬁcant
correlation with histopathologic severity.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Immunoglobulin A (IgA) nephropathy was ﬁrst described by
Berger and Hinglais [1] in 1968 and is now the most common
glomerulonephritis in the world, comprising about 20–45% of
primary glomerulonephritis [2]. The clinical course and prog-
nosis of IgA nephropathy is highly variable, ranging from
asymptomatic urinary abnormalities to severe, rapid decline in
kidney function. About 30% of patients are reported to progress
to end-stage renal disease (ESRD) in 20–25 years [3].n Society of Nephrology. Publi
c-nd/4.0/).
ology, Kyung Hee
gdaemun-gu, Seoul,Arterial hypertension, persistent proteinuria, elevated baseline
serum creatinine level, male sex, and older age at disease onset
are known markers of poor prognosis in IgA nephropathy [4–8].
Several studies have reported that the severity and prognosis of
IgA nephropathy are correlated with the expression levels of
speciﬁc markers such as serum erythropoietin, urinary N-acetyl-
b-D-glucosaminidase (NAG), beta-2-microglobulin, and nestin
[9–11]; however, none of these markers are sensitive or speciﬁc.
Predicting which patients with IgA nephropathy will progress to
ESRD remains controversial.
Histopathologic features such as glomerular sclerosis, tub-
ular atrophy, extension of immune deposits to the perivascular
space, and crescent formation may also aid in predicting risk
for progression of IgA nephropathy [12]. Recently, tubulointer-
stitial injury rather than glomerular injury is thought to be theshed by Elsevier. This is an open access article under the CC BY-NC-ND
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lointerstitial injury are currently being studied.
Kidney injury molecule-1 (KIM-1) is a type I transmembrane
glycoprotein with an ectodomain containing an immunoglo-
bulin-like domain and a mucin domain. This protein is usually
undetectable in normal kidneys but is expressed at high levels in
proximal tubular cells after ischemic or nephrotoxic injury as well
as other forms of injury including contrast-induced nephropathy
and renal allograft rejection [13,14]. A recent study suggests that
KIM-1 contributes not only to the regeneration process of tubular
epithelial cells through cell dedifferentiation in acute kidney
damage but also to tubular ﬁbrosis in some chronic renal disease.
Another study demonstrated that KIM-1 is upregulated in the
tubules and is associated with renal ﬁbrosis and inﬂammation in
patients with various chronic proteinuric kidney disease [15]. Few
studies, however, have linked KIM-1 with IgA nephropathy.
We therefore evaluated urinary KIM-1 in patients with IgA
nephropathy to determine its ability to reﬂect clinicopatholo-
gical severity and predict the response to treatment better
than baseline clinical and histopathologic parameters.Methods
Study participants
This study is part of an IgA nephropathy cohort study about
the effect of treatment and role of biomarkers in IgA nephro-
pathy in our hospital. We enrolled 40 patients with biopsy-
proven IgA nephropathy who visited Kyung Hee University
Hospital, Seoul, Korea between 2007 and June 2009, excluding
those patients with acute kidney injury, renal replacement
therapy, or urinary tract infections. We compared these
patients with healthy controls with an estimated glomerular
ﬁltration rate (eGFR) of more than 90 mL/min/1.73 m2 and no
apparent renal damage.
We recorded patients’ age and sex, measured their height,
weight, and blood pressure, and assessed blood urea nitrogen
(BUN), serum creatinine (sCr), hemoglobin, albumin, total
cholesterol, triglyceride, urinary protein, and creatinine levels.
eGFR was calculated using the modiﬁcation of diet in renal
disease study (MDRD) equation. All the samples were collected
prior to the commencement of immunosuppressive drugs.
Urine samples were collected from the ﬁrst spot urine on the
morning of the day of renal biopsy and stored at 70oC.
Proteinuria is expressed as urinary protein/creatinine ratio
(g/g Cr, UPCR).Figure 1. The mean histopathologic stages for patients with IgA
nephropathy. IgA, immunoglobulin A; TIF, tubulointerstitial ﬁbrosis;
TII, tubulointerstitial inﬂammation.Urine red blood cells were classiﬁed as Grades I–V: Grade I,
0–1/high-power ﬁeld (HPF); Grade II, 2–4/HPF; Grade III, 5–9/
HPF; Grade IV, 10–29/HPF; and Grade V, many/HPF.Measurement of urinary KIM-1 and creatinine levels
Urinary KIM-1 levels were measured using a human quan-
titative commercial enzyme-linked immunosorbent assay kit
(Cusabio Biotech Co., Hubei, China). Urine creatinine was
measured in same urine specimens, and adjusted urinary
KIM-1 levels were expressed as concentration of KIM-1/con-
centration of creatinine (ng/mg Cr).Histologic grading of IgA nephropathy
IgA nephropathy pathologic ﬁndings were classiﬁed using
the modiﬁed H. S. Lee grading system [16]. The percentage of
glomeruli affected by crescents/segmental sclerosis/global
sclerosis was speciﬁcally deﬁned for Grades I–V. The grading
was as follows: Grade I, normal or focal mesangial cell prolifera-
tion; Grade II, diffuse mesangial cell proliferation or o25% of
glomeruli with crescent (Cr)/segmental sclerosis (SS)/global
sclerosis (GS); Grade III, 25–49% of glomeruli with Cr/SS/GS;
Grade IV, 50–75% of glomeruli with Cr/SS/GS; and Grade V,
475% of glomeruli with Cr/SS/GS. In addition to the glomerular
ﬁndings, the tubulointerstitial grading score was based on the
degree of ﬁbrosis and inﬂammation in Grades 0–IV as follows:
Grade 0, no ﬁbrosis or inﬂammation; Grade I, focal ﬁbrosis or
inﬂammation; Grade II, mild global ﬁbrosis or inﬂammation;
Grade III, moderate global ﬁbrosis or inﬂammation; and Grade
IV, severe global ﬁbrosis or inﬂammation.Follow-up
sCr and UPCR were measured at 6 months after treatment.
We also measured ﬁnal sCr and UPCR of 31 patients who had
achieved at least 2 years of a follow-up visit for the evaluation
of long-term prognosis.Statistical analysis
Data are expressed as mean7standard deviation. Correla-
tions between urinary KIM-1 levels and biochemical and
clinical parameters were investigated by performing linear
and multiple regression analyses. We used a two-sample t test
and a χ2 test to compare continuous variables and categorical
variables, respectively. A Kruskal-Wallis test was used to
compare urinary KIM-1 levels among histologic stages. To
analyze disease progression, multiple regression analysis was
performed using changes in eGFR and proteinuria after treat-
ment as independent variables. A P value o0.05 was con-
sidered signiﬁcant. SPSS version 15.0 for Windows (SPSS Inc.,
Chicago, IL, USA) was used for all statistical analyses.Ethical statement
This study was approved by the Institutional Review Board
(IRB) in Kyung Hee Medical center (IRB approval number: KMC
IRB 0908-04). Written informed consent was obtained from all
study patients.
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Clinical characteristics
We investigated 40 patients with IgA nephropathy and 10
healthy controls. The mean initial sCr level of patients with IgA
nephropathy was not signiﬁcantly different from the mean
level in the control group, but eGFR was signiﬁcantly lower in
the IgA nephropathy patient group than the control group
(81.6729.7 mL/min/1.73 m2 versus 112.4711.5 mL/min/1.73 m2,
P¼0.01). The mean histologic stage for the patients with IgA
nephropathy was 2.0370.87 (H. S. Lee grading; Fig. 1). The
mean follow-up duration was 49.55 months. The mean urinary
KIM-1 levels were signiﬁcantly higher in IgA nephropathy
patients than controls (1.1771.51 ng/mg Cr vs. 0.2970.20 ng/mg
Cr, P¼0.001; Table 1, Fig. 2).Table 1. Clinical characteristics of patients with IgA nephropathy
and healthy controls
IgAN patients Healthy controls P
No 40 10 –
Age (y) 36.6712.9 37.379.6 0.965
Sex (M/F) 15/25 5/5 0.134
BMI (kg/m2) 22.6473.43 – –
Albumin (g/dL) 3.7870.60 – –
uKIM-1 (ng/mg Cr) 1.1771.51 0.2970.20 0.001
Serum creatinine, initial
(mg/dL)
1.1270.84 0.7170.09 0.178
eGFR, initial
(mL/min/1.73m2)
81.6729.7 112.5711.5 0.010
UPCR, initial (g/g Cr) 1.5871.47 –
uRBC grade – – –
0-1/HPF 3 (7.5)
2-4/HPF 3 (7.5)
5-9/HPF 8 (20.0)
10-29/HPF 11 (27.5)
many/HPF 15 (37.5)
Data are presented as n (%) or mean7SD, unless otherwise indicated.
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; IgAN,
immunoglobulin A nephropathy; HPF, high power ﬁeld; SD, standard
deviation; uKIM-1, urinary kidney injury molecule-1; UPCR, urinary
protein/creatinine ratio; uRBC, urine red blood cells.
Figure 2. The mean levels of urinary KIM-1 in patients with IgA
nephropathy and healthy controls. nP¼0.001 compared with healthy
controls. Cr, creatinine; IgA, immunoglobulin A; KIM-1, kidney injury
molecule-1.Association of urinary KIM-1 levels with clinical parameters
In univariate analysis, urinary KIM-1 levels were inversely
proportional to body mass index (BMI; r¼0.382, P¼0.018)
but had no association with initial serum Cr, albumin, eGFR,
UPCR, or uRBC grade. In multivariate analysis, BMI had no
statistical association with urinary KIM-1. As a predictor of
response to treatment, urinary KIM-1 levels showed no asso-
ciation with changes in eGFR or UPCR after treatment
(Table 2).
Association of urinary KIM-1 levels with
histopathology scores
When we investigated possible associations between urin-
ary KIM-1 levels and histopathologic grades, urinary KIM-1
levels were directly proportional to H. S. Lee Grades I–IV
(Grade I, 0.6170.48 ng/mg Cr; Grade II, 0.8570.97 ng/mg
Cr; Grade III, 1.5072.34 ng/mg Cr; and Grade IV, 3.8171.24
ng/mg Cr, P¼0.023) and to tubulointerstitial inﬂammation
from Grade 0 to Grade III (Grade 0, 0.7470.59 ng/mg Cr;
Grade I, 1.0471.59 ng/mg Cr; Grade II, 1.4170.62 ng/mg Cr;
Grade III, 3.8171.24 ng/mg Cr, P¼0.049; Fig. 3).Discussion
Our ﬁndings indicate that mean urinary KIM-1 levels, a
measure of tubular function, were signiﬁcantly higher in
patients with IgA nephropathy than in healthy controls. eGFR
was also lower in patients with IgA nephropathy compared
with the control group, but because there was no correlation
between eGFR and urinary KIM-1 levels in univariate analysis,
we concluded urinary KIM-1 levels are elevated in patients with
IgA nephropathy regardless of eGFR. Though IgA nephropathy is
a glomerular process, a tubular marker may be useful because
glomerular lesions induce tubular lesions through ﬁltered toxic
substances or hypertensive hemodynamic changes [17]. Inﬂam-
matory mechanisms are involved in the pathogenesis of tubular
lesions by increasing levels of urinary cytokines or growth
factors [18]. This pathophysiology can be associated with the
increase in the secretion of these proteins observed in
this study.
We also found that urinary KIM-1 levels had a signiﬁcant
correlation with pathologic ﬁndings such as the H. S. Lee
grading score and tubulointerstitial inﬂammation score in
patients with IgA nephropathy. Urinary KIM-1 levels as well
as the H. S. Lee glomerular grading scores were higher in
patients with more severe tubulointerstitial inﬂammation. Our
data show that even after adjustment with H. S. Lee grade,
urinary KIM-1 levels and tubulointerstitial inﬂammation were
directly related, suggesting urinary KIM-1 levels are a reﬂec-
tion of tubulointerstitial injury. These data in IgA nephropathy
are consistent with previous results that demonstrated upre-
gulation of KIM-1 in patients with various renal diseases and
an association with renal ﬁbrosis and inﬂammation [15]. This
study suggests that urinary KIM-1 may serve as a biomarker to
assess the severity of IgA nephropathy.
Our study revealed that urinary KIM-1 levels correlated
with H. S. Lee grade and tubulointerstitial inﬂammation but
not with any other clinical variables. It is possible, therefore,
that urinary KIM-1 levels can be used as a prognostic marker
even in patients with IgA nephropathy and clinically normal
Figure 3. The levels of urinary KIM-1 in patients with IgA nephropathy. (A) H. S. Lee grade and (B) tubulointerstitial inﬂammation. nP o0.05
compared with healthy control. †P o0.05 compared with Grade I and Grade II. ‡P o0.05 compared with Grade 0 and Grade I. Cr, creatinine; IgA,
immunoglobulin A; KIM, kidney injury molecule.
Table 2. Univariate and multivariate regression analysis results of the association between various clinical variables and urinary KIM-1 levels
Univariate Multivariaten
Unstandardized t P Unstandardized t P
/standardized b /standardized b
Serum Cr, initial 0.137/0.076 0.468 0.643
eGFR, initial 0.005/0.091 0.563 0.577
DeGFR 6m† 2.772/0.150 1.024 0.313
DeGFR ﬁnal† 0.004/0.102 0.545 0.585
UPCR, initial 0.091/0.089 0.551 0.585
DUPCR 6m† 0.132/0.130 1.768 0.087
DUPCR ﬁnal† 0.058/0.060 0.320 0.751
H. S. Lee grade 0.589/0.336 2.174 0.036 0.774/0.442 3.050 0.004
Glomerulosclerosis 0.303/0.206 1.280 0.209
TIF 0.391/0.160 0.986 0.331
TII 0.818/0.358 2.329 0.025 0.888/0.388 2.694 0.011
Age 0.026/0.224 1.420 0.164
Sex 0.834/0.271 1.735 0.091
BMI 0.172/0.382 2.484 0.018 0.124/0.268 1.825 0.078
Albumin 0.448/0.175 1.079 0.288
Use of immunosuppressant 0.529/0.211 1.333 0.190
n Adjusted by H. S. Lee grade, TII, BMI.
† D means an incremental or decremental change in a variable.
BMI, body mass index; Cr, creatinine; eGFR, estimated glomerular ﬁltration rate; KIM, kidney injury molecule; TIF, tubulointerstitial ﬁbrosis; TII,
tubulointerstitial inﬂammation; UPCR, urinary protein/creatinine ratio.
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is needed.
A recent study demonstrated the relationship between KIM-1
and the severity of IgA nephropathy. In this study, a total of 202
patients with IgA nephropathy were included, and there was a
positive correlation between urinary KIM-1 levels and the severity
of tubulointerstitial ﬁbrosis and inﬁltration [19]. These ﬁndings are
similar to our result, but we included patients with mild renal
dysfunction and proteinuria, and found correlation between
urinary KIM-1 levels and histopathologic severity. So our data
can suggest that even if patients with IgA nephropathy have a
relatively mild renal dysfunction and proteinuria, urinary KIM-1
levels might be thought to estimate the degree of glomerular
injury and tubulointerstitial inﬂammation.
In contrast to previous studies in patients with various
chronic renal diseases, patients with IgA nephropathy in our
study demonstrated no correlation between urinary KIM-1
levels and initial sCr. Instead, urinary KIM-1 levels showedweak correlations with eGFR and proteinuria, but these were
not statistically signiﬁcant. One explanation is that we included
patients with only mild renal dysfunction and proteinuria,
unlike the previous study that included patients with protei-
nuria 42.0 g/d and sCr levels 42.0 mg/dL [15,19].
In summary, our results indicate that urinary KIM-1 level
can be used as a noninvasive marker of pathologic severity in
patients with IgA nephropathy. Because the number of
patients enrolled in this study is small, future prospective
studies with a larger number of patients are required to
conﬁrm the association between these markers and the
pathophysiology and progression of IgA nephropathy.Conﬂict of interest
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